Analysts' Actions: DLB, GGP, MLM, ORCL
NEW YORK (
) --
CHANGE IN RATINGS
Accretive Health
(AH)
was downgraded to Sell at TheStreet Ratings.
Dolby
(DLB) - Get Report
was downgraded at JP Morgan from Overweight to Neutral. Company lacks near-term catalysts, JP Morgan said. $48 price target.
Extra Space Storage
(EXR) - Get Report
was downgraded at Jefferies to Hold from Buy. Valuation hard to ignore, Jefferies said.
General Growth
(GGP)
was upgraded at UBS to Buy from Neutral. $20 price target. Estimates were also increased on multiple near-term catalysts, UBS said.
Human Genome
( HGSI) was downgraded at Leerink Swann to Market Perform. See little upside potential to Glaxo's hostile bid, Leerink Swann said.
Highwood Properties
(HIW) - Get Report
was downgraded at Jefferies to Hold from Buy. $36 price target. Valuation now reflects fundamentals, Jefferies said.
Harsco
(HSC) - Get Report
was upgraded at Keybanc from Hold to Buy. $27 price target. Management change should improve shareholder value, Keybanc said.
Martin Marietta
(MLM) - Get Report
was downgraded at RBC Capital to Sector Perform. Valuation call, based on a $99 price target, RBC Capital said.
3M
(MMM) - Get Report
was downgraded at Bernstein from Outperform to Market Perform. $101 price target. Company is trying to balance between growth and margins, Bernstein said.
Vail Resorts
(MTN) - Get Report
was downgraded at Wells Fargo from Outperform to Market Perform. Company lacks near-term catalysts, Wells Fargo said.
Oracle
(ORCL) - Get Report
was downgraded at ThinkEquity from Buy to Hold. $28 price target. New analyst believes that the company lacks near-term catalysts, ThinkEquity said.
Pros Holdings
(PRO) - Get Report
was downgraded to Hold at TheStreet Ratings.
Prudential
(PRU) - Get Report
was upgraded at Credit Suisse from Equal-Weight to Overweight. Valuation call, based on a $66 price target, Credit Suisse said.
Teva Pharmaceutical
(TEVA) - Get Report
was downgraded at Needham from Strong Buy to Hold. Company is posting lower sales and withdrew its guidance, Needham said.
Marriott Vacations
(VAC) - Get Report
was upgraded at Goldman Sachs from Neutral to Buy. Valuation call, based on a $38 price target, Goldman Sachs said.
STOCK COMMENTS / EPS CHANGES
BMC Software
(BMC)
price target was raised at Jefferies to $48. Operational improvements place company in a better position, Jefferies said.
Cisco
(CSCO) - Get Report
estimates, price target were reduced at FBR Capital Markets. Shares are now seen reaching $20. Estimates were also cut, given the company's new guidance, FBR said. Market Perform rating.
Cisco Systems numbers were lowered at Oppenheimer. Shares are now seen reaching $22. Estimates were also lowered on guidance below consensus, Oppenheimer said. Outperform rating.
Commvault
(CVLT) - Get Report
estimates, price target were raised at Credit Suisse. Shares are now seen reaching $50. Estimates were also increased, as Simpana is driving growth, Credit Suisse said. Neutral rating.
Dean Foods
(DF) - Get Report
numbers were raised at Credit Suisse. Shares are now seen reaching $16. Estimates were also increased, given better business momentum, Credit Suisse said. Neutral rating.
Ingersoll-Rand
(IR) - Get Report
price target was boosted at Bank of America/Merrill Lynch to $50. Activist investor could help unlock shareholder value, BofA/Merrill said.
Priceline.com
(PCLN)
estimates were increased at Benchmark through 2013. Bookings growth remains strong, Benchmark said. Buy rating and $840 price target.
Rosetta Resources
(ROSE) - Get Report
numbers were lowered at Credit Suisse. Estimates were cut through 2014. Company is seeing slower production growth and lower prices, Credit Suisse said. Outperform rating and new $70 price target.
Spectrum Brands
(SPB) - Get Report
numbers were increased at Credit Suisse. Estimates were boosted through 2013. Company is seeing higher sales and cutting costs, Credit Suisse said. Outperform rating and new $40 price target.
Teva Pharmaceutical estimates were cut at Morgan Stanley through 2014. Company is facing higher generic competition and has limited pipeline visibility, Morgan Stanley said. Equal-Weight rating and new $47 price target.
>To submit a news tip, email:
.
READERS ALSO LIKE:
>>3 Hot Stocks for a Sideways Market
>>Prudential Financial Gets Two Upgrades
Follow
TheStreet
on
and become a fan on
This article was written by a staff member of TheStreet.
